Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay

Gynecologic Oncology

Volumn 53, Issue 1, 1994, Pages 44-49

  Untch, Michael ^b   Sevin, Bernd Uwe ^a   Perras, James P ^a   Angioli, Roberto ^c   Untch, Andrea ^a   Hightower, Randolph D ^a   Koechli, Ossi ^d   Averette, Hervy E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0028180548     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1994.1085     Document Type: Article

References (37)

1. Rowinsky, E. K., Cazenave, L. A., and Donehower, R. C. Taxol: A novel investigational antimicrotubule agent, J. Nati Cancer Inst. 82, 1247-1259 (1990).
2. Wani, M. C., Taylor, H. L., and Wall, M. E. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, J. Am. Chem. Soc. 93, 2325-2327 (1971).
3. Riondel, J., Jacrot, M., and Picot, F. Therapeutic response to taxol of six human tumors xenografted into nude mice, Cancer Chemo-ther. Pharmacol. 17, 137-142 (1986).
4. Fan, D., Ajani, J. A., and Baker, F. L. Comparison of antitumor activity of Standard and investigational drugs at équivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: An in vivo method of Screening new drugs, Eur. J. Cancer Clin. Oncol. 23, 1469-1476 (1987).
5. Roytta, M., Laine, K. M., and Harkonen, P. Morphological studies on the effect of taxol on cultured human prostatic cells, Prostate 11, 95-106 (1987).
6. Ringel, I., and Horwitz, S. B. Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol, J. Natl. Cancer Inst. 83, 288-291 (1991).
7. Citardi, M., Rowinsky, E. K., Schaefer, K. L., and Donehower, R. C. Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine, Proc. Am. Assoc. Cancer Res. 31, 2431 (1990).
8. Untch, M., Sevin, B. U., Baibl, A., Perras, J. P., Angioli, R., Hightower, R. D., and Averette, H. E. Comparison of taxo) cy-totoxicity in gynecologic cancer cell Unes and fresh tumor tissue with the ATP Cell Viability assay, Proc. Am. Soc. Clin. Oncol. 10, 608 (1991).
9. McGuire, W. P., Rowinsky, E. K., and Rosenshein, N. B., Taxol: A unique antineoplastic agent with significant activity in advanced ovarían epithelial neoplasms, Ann. Intern. Med. 111, 273-279 (1989).
10. Rowinsky, E. K., Gilbert, M., and Mc Guire, W. P. Sequences of taxol and cisplatin: A phase I and pharmacologie study, J. Clin. Oncol. 9, 1692-1703 (1991).
11. Thigpen, T., Blessing, J., and Bail, H. Phase II trial of taxol as second-line therapy for ovarían carcinoma: A gynecologic oncology group study, Proc. Am. Soc. Clin. Oncol. 9, 604 (1990).
12. Holmes, F. A., Walters, R. S., and Theriault, R. L. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer, J. Natl. Cancer Inst. 83, 1793-1805 (1991).
13. McGuire, W. P., Hoskins, W. J., and Brady, M. F. A phase III trial comparing cisplatin/cytoxan and dsplatin/taxol in advanced ovarían cancer. Proc. Am. Soc. Clin. Oncol. 12, 255 (1993).
14. Garewall, H., Ahmann, F., and Schifman, R. ATP assay. Ability to distinguish cytostatic from cytocidal anticancer drug effect, J. Natl. Cancer Inst. 77, 1039-1045 (1986).
15. Kangas, L., Groenroos, M., and Nieminen, A. Bioluminescence of cellular ATP: A new method for evaluating cytotoxic agents in vitro, Med. Biol. 62, 338-343 (1984).
16. Kuzmits, R., Rumpold, H., and Mueller, M. The use of bioluminescence to evalúate the influence of chemotherapeutic drugs on ATP levels of malignant cell lines, J. Clin. Chem. Clin. Biochem. 24, 293-298 (1986).
17. Sevin, B. Ü., Peng, Z., and Perras, J. P. Application of an biol-uminescence assay in human tumor chemosensitivity testing, Gynecol. Oncol. 31, 191-204 (1988).
18. Gerhardt, R. T., Perras, J. P., Sevin, B. Ü., Petru, E., Ramos, R., Guerra, L., and Averette, H. E. Characterization of in vitro chemosensitivity of perioperative human ovarían maiignancies by ATP chemosensitivity analysis, Am. J. Obstet. Gynecol. 165, 245-255 (1991).
19. Untch, M., Sevin, B. U., Perras, J. P., R. Angioli, Baibl, A., Nguyen, H. N., Hightower, R. D., and Averette, H. E. Evaluation of chemosensitivity to pirarubicin and other chemotherapeutic agents in primary and récurrent gynecologic maiignancies, Gynecol. Oncol. 47, 172-178 (1992).
20. Peng, Z. L., Perras, J. P., and Sevin, B. U. ATP-bioluminescence assay for évaluation of tumor chemosensitivity, Proc. Am. Assoc. Cancer Res. 28, (1987).
21. Petru, E., Sevin, B. U., Perras, J. P., Boike, G., Ramos, R., Nguyen, H. N., and Averette, H. E. Comparative chemosensitivity profiles in four human ovarían carcinoma cell lines measuring ATP bioluminescence, Gynecol. Oncol. 38, 155-160 (1990).
22. Nguyen, H. N., Sevin, B. U., Averette, H. E., Perras, J. P., Donato, D., and Penalver, M. Comparative évaluation of single and combination chemotherapy in uterine cancer cell lines, Gynecol. Oncol. 42, 227-232 (1991).
23. Alberts, D., and Chen, G. Tabular summary of pharmacokinetic Parameters relevant to in vitro drug assay, in Cloning of human tumor stem cells (S. Salmón, Ed.), Liss, New York, pp. 351-359 (1980).
24. Wiemik, P. H., Schwartz, E. L., and Straumann, J. P. Phase I clinicai and pharmacokinetic study of taxol, Cancer Res. 47, 2486-2493 (1987).
25. Chou, T., and Talaly, P. Quantitative analysis of dose-effect re-lationships: The combined effects of multiple drugs or enzyme in-hibitors, Adv. Enzyme Regul. 22, 27-55 (1984).
26. Valeriote, F., and Lin, H. Synergistic interaction of anticancer agents: A cellular perspective, Cancer Chemother. Rep. 59, 895-900 (1975).
27. Momparler, R. L. In vitro systems for évaluation of combination chemotherapy, Pharmacol. Ther. 8, 21-35 (1980).
28. Prosnitz, L. R., Kapp, D. S., and Weissberg, J. B. Radiotherapy, N. Engl. J. Med. 309, 834-840 (1983).
29. Piver, M. S., and Rose, P. G. Chemotherapy of ovarían cancer, in Chemotherapy of Gynecologic Cancer (G. Deppe, Ed.), Wiley-Liss, New York, pp. 175-216 (1990).
30. Piver, M. S., Lele, S. B., Marchetti, D. L., Baker, T. R., Tsukada, Y., and Emrich, L. J. The impact of aggressive debulking surgery and cisplatin based chemotherapy on progression free survival in stage III and IV ovarían carcinoma, J. Clin. Oncol. 6, 983-989 (1988).
31. Lele, S. B., Piver, M. S., Malfetano, J. Cisplatin plus VP 16-213 in refractory ovarian carcinoma, Am. J. Clin. Oncol. 10, 21-22 (1987).
32. Stanhope, C. R., Smith, J. P., and Rutledge, F. Second trial drugs in ovarian cancer, Gynecol. Oncol. 17, 52-58 (1977).
33. Dittrich, C. Chemosensitivitätstestung, in Klonieren von soliden Tumoren (C. Dittrich Ed.), Springer Verlag, Wien New York, pp. 94-95, (1987).
34. Sevin, B. U., Perras, J. P., and Averette, H. E. Chemosensitivity testing in ovarian cancer, Cancer Suppl. 7, 1613-1620 (1993).
35. Trimble, E. L., Adams, J. D., Vena, D., Hawkins, M. J., Friedman, M. A., Canetta, R., Onetto N., Hayn, R., and Arbuck, S. G. Taxol in patients with platinum-refractory ovarian cancer, Proc. Am. Soc. Clin. Oncol. 12, 261 (1993).
36. Welander, C. E., Homesley, H. D., and Jobson, V. W. In vitro chemotherapy testing of gynecologic tumors: basis for planning therapy? Am. J. Obstet. Gynecol. 147, 188-195 (1983).
37. Moon, T. E. Quantitative and statistical analysis of the association between in vitro and in vivo studies, in Cloning of human tumor stem cells (S. E. Salmon, Ed.), Liss, New York, pp. 209-221 (1980).